lamivudine + tenofovir disoproxil fumarate + lopinavir + ritonavir

The drug combination "lamivudine + tenofovir disoproxil fumarate + lopinavir + ritonavir" is a four-drug antiretroviral regimen used in the treatment of HIV infection. This combination brings together nucleoside reverse transcriptase inhibitors (lamivudine and tenofovir disoproxil fumarate) with a protease inhibitor (lopinavir) boosted by a pharmacokinetic enhancer (ritonavir). ## Mechanism of Action This combination works through multiple mechanisms to suppress HIV replication: - **Lamivudine (3TC)** is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase, preventing viral DNA synthesis. - **Tenofovir disoproxil fumarate (TDF)** is also an NRTI that blocks reverse transcriptase activity through a similar mechanism. - **Lopinavir** is a protease inhibitor that prevents the cleavage of viral polyproteins, inhibiting the formation of mature viral particles. - **Ritonavir** primarily serves as a pharmacokinetic enhancer (booster) that inhibits the metabolism of lopinavir, increasing its plasma concentration and efficacy. ## Clinical Evidence Research has shown that dual therapy with lopinavir-ritonavir plus lamivudine has non-inferior therapeutic efficacy compared to triple therapy regimens for maintenance of HIV viral suppression. While the specific four-drug combination isn't explicitly mentioned in the search results as a fixed-dose combination product, the components are used together in various HIV treatment regimens. The FDA has listed "Abacavir+lamivudine+lopinavir+ritonavir" as a four-drug combination needed for pediatric formulations under PEPFAR (President's Emergency Plan for AIDS Relief), indicating the importance of similar multi-drug combinations in HIV treatment. ## Available Formulations The individual components are available as separate medications or as part of other fixed-dose combinations: - Lamivudine and tenofovir disoproxil fumarate are available as a dual combination under brand names Cimduo and Temixys. - Lopinavir and ritonavir are available as a fixed-dose combination under the brand name Kaletra. This four-drug regimen represents a comprehensive approach to HIV treatment, targeting multiple stages of the viral life cycle to effectively suppress viral replication and maintain immune function in people living with HIV.